Klaria Pharma

The year in brief

- Net sales amounted to 5.9 MSEK (0.0 MSEK)

- Other operating income amounted to 0.7 MSEK (37.5 MSEK)

- R&D costs amounted to 51.4 MSEK (63.5 MSEK)

- Profit/loss after tax amounted to -63.8 MSEK (-53.5 MSEK)

- Earnings per share amounted to -1.10 SEK (-1.03 SEK)

- Cash flow from operations amounted to -49.7 MSEK (-24.8 MSEK)

- Shareholder’s equity as of December 31, 2022 amounted to 76.1 MSEK (69.4 MSEK)

- Cash and cash equivalents as of December 31, 2022 amounted to 16.8 MSEK (25.5 MSEK)